A Note on Research Status

This article summarises published preclinical and in vitro literature. GHK-Cu is supplied by Velyx Research Ltd strictly as a research compound for laboratory research purposes only.

What Is GHK-Cu?

GHK-Cu is a naturally occurring copper-binding tripeptide complex consisting of three amino acids — glycine, L-histidine, and L-lysine — chelated to a copper(II) ion. Its systematic name is glycyl-L-histidyl-L-lysine copper(II) complex. The molecular formula of the GHK tripeptide is C₁₄H₂₃N₆O₄ with a molecular weight of 340.37 daltons; in its copper-chelated form (GHK-Cu) the molecular weight is approximately 403.91 daltons. Its CAS registry number is 49557-75-7.

The peptide was first isolated from human plasma albumin in 1973 by biochemist Dr. Loren Pickart, then at the University of California San Francisco, during research into why plasma from young adults (aged 20–25) stimulated markedly different protein synthesis patterns in aged liver tissue compared to plasma from older donors. Pickart identified the active fraction and, after four years of further investigation, isolated the tripeptide responsible, publishing the finding in 1977.

GHK occurs naturally in human plasma, saliva, and urine. It is also present as an embedded sequence within the alpha-2(I) chain of Type I collagen, and is released as a breakdown product when collagen in the extracellular matrix is degraded. That endogenous origin is part of why the compound has attracted sustained research interest — it's a naturally occurring degradation product rather than a synthetic novelty.

GHK-Cu is not supplied by Velyx Research Ltd as a licensed medicine or as a product for human or veterinary use. It is supplied exclusively as a research compound for laboratory research purposes.

Molecular Structure and the Role of Copper

Understanding GHK-Cu requires understanding what the copper ion contributes to the complex's chemistry.

Copper is a transitional metal essential to all eukaryotic life. Because it can alternate between oxidised Cu(II) and reduced Cu(I) states, it functions as an electron transfer cofactor in numerous enzymatic reactions. A group of enzymes — cuproenzymes — use changes in copper oxidation states to catalyse biochemical reactions including cellular respiration (cytochrome c oxidase), antioxidant defence (ceruloplasmin, superoxide dismutase), and connective tissue formation (lysyl oxidase).

Lysyl oxidase is the enzyme most directly relevant to GHK-Cu's documented in vitro effects on connective tissue — it catalyses the cross-linking of collagen and elastin fibres, the process that gives mature collagen its tensile strength. GHK-Cu's function as a copper-binding complex is one proposed mechanism for how it interacts with copper-dependent enzymatic processes in cell-culture models of matrix formation.

The tripeptide sequence has high affinity for Cu(II) ions, with the imidazole ring of histidine and the terminal amino groups of glycine and lysine forming the coordination complex. This copper-chelating property means GHK can function both as a copper-transport molecule in vitro and, in cell-free assay systems, as an antioxidant that sequesters free copper ions which would otherwise catalyse Fenton reactions generating hydroxyl radicals.

Molecular Mechanisms: How GHK-Cu Acts on Cells

Unlike most signalling molecules that operate through a single defined receptor or pathway, GHK-Cu has been documented across the published in vitro and preclinical literature to influence several cellular processes.

Extracellular Matrix Synthesis and Remodelling

The foundational mechanism in GHK-Cu research is its effect on fibroblast-mediated extracellular matrix (ECM) production. Maquart et al. (1988), publishing in FEBS Letters (PMID: 3169264), demonstrated that GHK-Cu stimulated collagen synthesis in fibroblast cultures beginning at concentrations between 10⁻¹² and 10⁻¹¹ M, with maximum stimulation at 10⁻⁹ M. Critically, the effect was independent of any change in cell number, indicating enhanced synthetic activity per cell rather than proliferation.

This collagen-stimulating effect has been replicated across multiple independent research groups, with reported increases in Type I and Type III collagen, elastin, decorin, and glycosaminoglycan production, alongside regulation of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) — a balance that distinguishes GHK-Cu mechanistically from a compound that simply stimulates matrix production without any regulatory counterbalance.

Angiogenesis

In cell-based assay systems, GHK-Cu has been documented to upregulate basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) expression, and to act as a chemoattractant for capillary endothelial cells — a property first characterised by Raju et al. (1984) in chemotaxis assays. Wang et al. (2017), publishing in Wound Repair and Regeneration, examined GHK-Cu liposome formulations in a mouse scald-wound model, reporting higher capillary density in treated wounds.

Antioxidant Mechanisms

In cell-free and cell-based assay systems, GHK has been shown by ESR spectroscopy to quench hydroxyl and peroxyl radicals, with some research reporting stronger radical-quenching activity than glutathione (GSH) under the same assay conditions.

In macrophage cell culture models, GHK-Cu pretreatment has been associated with decreased reactive-oxygen-species levels following lipopolysaccharide challenge, alongside increased superoxide dismutase (SOD) activity and modulation of NF-κB p65 and p38 MAPK signalling.

The antioxidant activity described in the literature operates through two proposed mechanisms: direct free-radical quenching by the peptide-copper complex, and upregulation of endogenous antioxidant enzyme expression (SOD, catalase, glutathione peroxidase) in cell-culture models.

Gene Expression Modulation

Pickart, Vasquez-Soltero, and Margolina (2015) used the Broad Institute's Connectivity Map (CMap) database — a database mapping how compounds alter gene activity across cultured human cell lines — to characterise the scope of GHK-Cu's influence on gene expression in this model system. The analysis found GHK-Cu associated with expression changes across a substantial proportion of the genes screened at a ≥50% change threshold.

The pattern of modulation observed skewed toward genes associated with tissue-repair and antioxidant-defence pathways, alongside downregulation of genes associated with inflammatory signalling.

The Connectivity Map methodology itself is well-established and widely used in drug-discovery research; the gene-expression finding is methodologically sound, though the CMap database reflects a cultured-cell-line model and the biological interpretation of the result continues to be refined in subsequent literature.

Published Preclinical Findings

Wound Healing Research

Maquart et al. (1993), publishing in the Journal of Clinical Investigation, conducted in vivo studies in rat experimental wounds, reporting that topical GHK-Cu stimulated connective tissue accumulation, increased collagen deposition, and improved wound organisation compared to controls — one of the first controlled in vivo demonstrations of the effect.

Canapp et al. (2003), publishing in Veterinary Surgery, examined GHK-Cu in an ischaemic open-wound model — wounds with impaired blood supply — and reported improved wound closure rates in GHK-Cu-treated animals compared to controls in that model.

Extracellular Matrix Research in Fibroblast Models

Cultured human dermal fibroblast studies, building on Maquart's foundational work, have reported concentration- and duration-dependent increases in Type I, III, and IV collagen synthesis across multiple independent replications.

Lung Gene-Expression Research

Campbell et al. (2012), publishing in Genome Medicine, used gene-expression database analysis to show that the GHK signature reversed a pathological lung-tissue expression pattern associated with emphysema in the dataset examined — extending research interest in the compound beyond dermal and wound-healing contexts specifically. This is a single gene-signature analysis rather than an interventional efficacy study.

Endogenous Plasma Levels

Published data documents plasma GHK concentrations of approximately 200 ng/mL in samples from individuals aged 20–25, compared to approximately 80 ng/mL in samples from individuals around age 60. That age-related difference in circulating concentration is part of why the compound remains of interest to researchers working on cellular-ageing and matrix-signalling pathways specifically — it is a correlational finding in the published data, not a claim about outcome or effect.

Purity Standards and COA Documentation

Research-grade GHK-Cu is characterised by reverse-phase HPLC purity assessment, with 99%+ the standard for research-grade compounds. For GHK-Cu specifically, purity assessment has an additional dimension beyond peak-area analysis: confirmation that the copper-chelate complex is intact. A sample measuring 99% pure by HPLC but with disrupted copper chelation is not the same compound as 99% pure intact GHK-Cu.

Mass spectrometry (MS) can confirm the molecular weight of the copper complex (approximately 403.91 Da), distinguishing it from the unchelated tripeptide (340.37 Da).

Regulatory and Compliance Context (UK)

The regulatory treatment of research compounds in the UK can depend on the specific substance, its intended purpose, how it is presented and marketed, and the legislation that applies.

The Medicines and Healthcare products Regulatory Agency (MHRA) considers factors including the claims made about a product, its pharmacological, metabolic or immunological properties, its primary intended purpose, and how it is presented to the public through labelling, packaging, promotional material, websites and advertising.

GHK-Cu is not supplied by Velyx Research Ltd as a licensed medicine or as a product for human or veterinary use. Velyx Research Ltd supplies GHK-Cu as a research compound for laboratory research purposes only and does not make therapeutic, diagnostic or clinical claims regarding the product.

This article is provided for informational and educational purposes based on published scientific literature. It does not constitute legal, regulatory, medical or professional advice. Where a specific regulatory determination is required, appropriate professional advice should be obtained.